Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Dysregulation of the Placenta in HIV-positive, ART-Treated Pregnancies

EF 2025-26

Résumé
The use of antiretroviral therapy (ART) to control the Human Immunodeficiency Virus (HIV) is highly effective. ART is taken during pregnancy by those infected with HIV to prevent vertical transmission of the virus to the child. Despite this benefit, the use of ART during pregnancy has also been associated with various adverse birth outcomes, including preeclampsia, stillbirths, preterm births, and small for gestational age births. In particular, one class of ART, protease inhibitors, has been associated with these adverse birth outcomes and dysregulation of angiogenesis in the placenta. This proposal aims to investigate which ARTs are the safest for use during pregnancy. Currently, numerous protease inhibitors, specifically Atazanavir, Darunavir, and Lopinavir, are recommended by the World Health Organization (WHO) for use during HIV-positive pregnancies. Dolutegravir, an Integrase Strand Transfer Inhibitor, is also recommended by the WHO for use in HIV-positive pregnancies. Placental angiogenesis is mediated by a number of factors, including placental growth factor (PlGF), vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 1 (Flt-1), and vascular endothelial growth factor receptor 2 (KDR). We will investigate levels of these factors, as well as their ligand-receptor ratios, in placentas across various ART treatments and HIV-negative controls. This will help us better understand what might be driving the angiogenic dysregulation and adverse birth outcomes seen in protease inhibitor-treated pregnancies. We will also investigate markers of placental pathology to measure how and which drugs are impacting placental health.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
582685
Name
Lazaris Zoe
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Dysregulation of the Placenta in HIV-positive, ART-Treated Pregnancies
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Adverse Birth Outcomes; Angiogenesis; Antiretroviral Therapy; Hiv; Integrase Strand Transfer Inhibitors; Placenta; Placental Growth Factor; Pregnancy; Protease Inhibitors; Vascular Endothelial Growth Factor
Abstract
The use of antiretroviral therapy (ART) to control the Human Immunodeficiency Virus (HIV) is highly effective. ART is taken during pregnancy by those infected with HIV to prevent vertical transmission of the virus to the child. Despite this benefit, the use of ART during pregnancy has also been associated with various adverse birth outcomes, including preeclampsia, stillbirths, preterm births, and small for gestational age births. In particular, one class of ART, protease inhibitors, has been associated with these adverse birth outcomes and dysregulation of angiogenesis in the placenta. This proposal aims to investigate which ARTs are the safest for use during pregnancy. Currently, numerous protease inhibitors, specifically Atazanavir, Darunavir, and Lopinavir, are recommended by the World Health Organization (WHO) for use during HIV-positive pregnancies. Dolutegravir, an Integrase Strand Transfer Inhibitor, is also recommended by the WHO for use in HIV-positive pregnancies. Placental angiogenesis is mediated by a number of factors, including placental growth factor (PlGF), vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 1 (Flt-1), and vascular endothelial growth factor receptor 2 (KDR). We will investigate levels of these factors, as well as their ligand-receptor ratios, in placentas across various ART treatments and HIV-negative controls. This will help us better understand what might be driving the angiogenic dysregulation and adverse birth outcomes seen in protease inhibitor-treated pregnancies. We will also investigate markers of placental pathology to measure how and which drugs are impacting placental health.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lazaris, Zoe
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~